Related Experiment Video

Updated: Oct 9, 2025

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.8K

Predictors of positive response to beta-blockers for treatment of premature ventricular complexes

Serdar Demir1, Kamil Gulsen1, Alper Kepez2

  • 1Kartal Koşuyolu Heart Training and Research Hospital, Cardiology Clinic, Istanbul, Turkey.

Journal of Electrocardiology
|December 18, 2021
PubMed

Insights

Beta-blocker therapy for premature ventricular complexes (PVCs) is more effective in patients with a positive correlation between heart rate and PVCs. PVC QRS width also predicts treatment success for these arrhythmias.

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Premature ventricular complexes (PVCs) are common arrhythmias.
  • Beta-blockers are frequently used for PVC treatment.
  • Predictors of beta-blocker efficacy for PVCs require further investigation.

Purpose of the Study:

  • To identify factors predicting the antiarrhythmic effect of beta-blockers on PVCs.
  • To evaluate the relationship between patient characteristics and response to beta-blocker therapy.

Main Methods:

  • Retrospective analysis of 190 patients treated with beta-blockers for PVCs.
  • Comparison of Holter recordings before and after treatment initiation.
  • Logistic regression analysis to identify independent predictors of response.

Main Results:

  • 32.1% of patients showed at least a 50% reduction in PVC burden.
  • Responders had a significantly higher prevalence of fast heart rate-PVC status (73.8% vs. 48.1%).
  • Independent predictors of positive response included fast HR-PVC status (OR 2.935) and PVC QRS width (OR 0.971).

Conclusions:

  • Fast heart rate-PVC status is a positive predictor of beta-blocker success.
  • PVC QRS width is a negative predictor of beta-blocker success.
  • These findings may guide clinical treatment decisions for PVC management.
Abstract

Keywords:
Beta-blockerDiurnal variability of premature ventricular complexesHolter recordingPremature ventricular complex

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.0K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
471
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.1K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.0K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
979
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
197
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
772